51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)ICAAC 2011: Raltegravir is Effective and Well-tolerated in Diverse Populations with HIV
- Details
- Category: HIV Treatment
- Published on Monday, 19 September 2011 00:00
- Written by Merck
The HIV integrase inhibitor raltegravir (Isentress) works well for both men and women and people of diverse racial/ethnic groups, according to data from the REALMRK trial presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.
ICAAC 2011: Didanosine, Higher HCV Viral Load Predict Liver Fibrosis in HIV/HCV Coinfected People
- Details
- Category: Fibrosis & Cirrhosis
- Published on Monday, 19 September 2011 00:00
- Written by Liz Highleyman
Use of didanosine (ddI, Videx) -- along with higher hepatitis C virus (HCV) RNA level, male sex, and older age -- was a significant risk factor for liver fibrosis in people with HIV/HCV coinfection, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.
ICAAC 2011: HCV Drug Telaprevir Shows No Problematic Interactions with Raltegravir
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 04 January 2011 00:00
- Written by Liz Highleyman
The new hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) does not appear to have clinically relevant drug-drug interactions with the HIV integrase inhibitor raltegravir (Isentress), according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
ICAAC 2011: BMS-790052 plus Standard Therapy Cures Most Genotype 1 Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 19 September 2011 00:00
- Written by Liz Highleyman
Up to 83% of treatment-naive people with difficult-to-treat genotype 1 hepatitis C virus (HCV) infection achieved sustained virological response (SVR) with the experimental HCV NS5A inhibitor BMS-790052 plus pegylated interferon and ribavirin, according to data presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.
Web Design and Development by